Travis Murdoch, HI-Bio CEO
HI-Bio outlines data that sparked $1.15B Biogen buyout
Days after getting acquired by Biogen, Human Immunology Biosciences revealed Phase 2 data that helped seal the deal.
In the trial, which looked at the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
